Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | ULK1 | O75385 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207166 | 1.00 | HCRTR1 (0.46) | HCRTR1HCRTR2KDRAURKAAURKB | |
| SCHEMBL19256063 | 1.00 | HCRTR1 (0.46) | HCRTR1HCRTR2KDRAURKAAURKB | |
| SCHEMBL19256523 | 0.80 | HCRTR1 (0.44) | HCRTR1 | |
| SCHEMBL19256528 | 0.80 | HCRTR1 (0.44) | HCRTR1 | |
| SCHEMBL19256527 | 0.80 | HCRTR1 (0.44) | HCRTR1 | |
| Bromide SCHEMBL19207100 | 0.79 | HCRTR1 (0.44) | HCRTR1 | |
| SCHEMBL24381383 | 0.79 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL19256525 | 0.76 | HCRTR1 (0.42) | HCRTR1 | |
| SCHEMBL19207012 | 0.76 | HCRTR1 (0.42) | HCRTR1 | |
| SCHEMBL24381394 | 0.76 | HCRTR1 (0.42) | HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| WO-2017139603-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885HCRTR2 1/4885KDR 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.